907. Outcomes Research: Plasma Cell Disorders: Poster II
0 activities
Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
1 activities
Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma
1 activities
Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma
Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
1 activities
Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center
1 activities
Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center
Understanding Frontline Therapy Pattern, Attrition Rates and Survival Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Underwent Transplant
1 activities
Understanding Frontline Therapy Pattern, Attrition Rates and Survival Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Underwent Transplant
Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment:
1 activities
Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment:
Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
1 activities
Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe
1 activities
The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe
Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center
1 activities
Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center
Disparities in Outcomes for Patients with Multiple Myeloma: A SEER Database Analysis
1 activities
Disparities in Outcomes for Patients with Multiple Myeloma: A SEER Database Analysis
Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
1 activities
Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
1 activities
Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
Racial Differences in Proportion of Myeloma Cases Attributable to Modifiable Risk Factors in the United States, 2016-21
1 activities
Racial Differences in Proportion of Myeloma Cases Attributable to Modifiable Risk Factors in the United States, 2016-21
Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
1 activities
Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group
1 activities
Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group
CAR-T Therapy Showdown: Comparative Efficacy and Safety of of Ide-Cel (Idecabtagene vicleucel) and Cilta-Cel (Ciltacabtagene Autoleucel) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study
1 activities
CAR-T Therapy Showdown: Comparative Efficacy and Safety of of Ide-Cel (Idecabtagene vicleucel) and Cilta-Cel (Ciltacabtagene Autoleucel) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study
Real-World Data of Maintenance Therapy for Newly Diagnosed Multiple Myeloma: Ixazomib Versus Lenalidomide
1 activities
Real-World Data of Maintenance Therapy for Newly Diagnosed Multiple Myeloma: Ixazomib Versus Lenalidomide
Treatment Journey of Octogenarian Patients Outside Clinical Trials
1 activities
Treatment Journey of Octogenarian Patients Outside Clinical Trials
Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment
1 activities
Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment
Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
1 activities
Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
1 activities
Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
A New Frailty Assessment Model Incorporating Gait Speed and Grip Strength for Multiple Myeloma and Consistency Analysis with IMWG-FI
1 activities
A New Frailty Assessment Model Incorporating Gait Speed and Grip Strength for Multiple Myeloma and Consistency Analysis with IMWG-FI
Daratumumab, Bortezomib and Dexamethasone for Previously Treated Myeloma – Comparing Real-World Outcomes in England to the Castor Phase III Clinical Trial
1 activities
Daratumumab, Bortezomib and Dexamethasone for Previously Treated Myeloma – Comparing Real-World Outcomes in England to the Castor Phase III Clinical Trial
Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research
1 activities
Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research
Frontiers in Myeloma: Barriers to Clinical Trial Participation in Multiple Myeloma
1 activities
Frontiers in Myeloma: Barriers to Clinical Trial Participation in Multiple Myeloma
Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
1 activities
Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
A Pragmatic Approach for Quantifying Treatment Tolerability in Multiple Myeloma Clinical Practice Using Patient-Reported Outcomes (PROs)
1 activities
A Pragmatic Approach for Quantifying Treatment Tolerability in Multiple Myeloma Clinical Practice Using Patient-Reported Outcomes (PROs)
Smoldering Multiple Myeloma in Latin America- Risk Stratification
1 activities
Smoldering Multiple Myeloma in Latin America- Risk Stratification
Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
1 activities
Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience
1 activities
Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience
Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
1 activities
Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
Real-World Evidence for Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients
1 activities
Real-World Evidence for Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients
Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
1 activities
Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
1 activities
Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
1 activities
Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)